IASLC 21st World Conference on Lung Cancer - Results from the Virtual Presidential Symposium
Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)
Data from ORIENT-11 show that the addition of sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. More info
Interim results of the randomized, open-label, phase III eXalt3 trial showed that ensartinib excelled over crizotinib in patients with locally advanced or metastatic ALK-positive NSCLC who were naïve to ALK-targeted therapy. More info